Mirla Avila, MD, explains why staying consistent with treatment is essential to help reduce the risk of attacks and long-term disability.
Transcript
With NMOSD being a rare disease, the amount of patients that we have in trials is much less than with multiple sclerosis. You know, with MS, we have thousands and thousands.
And with NMOSD, the experience that we have throughout the years has changed dramatically — just because now they can be diagnosed differently. All the criteria has changed, has improved. We have more knowledge about it.
And now that we have FDA-approved medications for these patients, it’s very important for them not to get burned out from the treatment because this is a disease that is very debilitating.
And if you have an attack, there’s a very high chance that you’re going to develop disability from that attack.